Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers

Larry W. Fislier, Alka Jain, Matt Tayback, Neal S Fedarko

Research output: Contribution to journalArticle

Abstract

Purpose: Members of the small integrin binding ligand N-linked glycoprotein (SIBLING) gene family have the capacity to bind and modulate the activity of matrix metalloproteinases (MMPs). The expression levels of five SIBLING gene family members [bone sialoprotein (BSP), osteopontin (OPN), dentin matrix protein 1 (DMP1), matrix extracellular phosphoglycoprotein (MEPE), and dentin sialophosphoprotein (DSPP)] and certain MMPs were determined using a commercial cancer array. Experimental Design: Cancer profiling arrays containing normalized cDNA from both tumor and corresponding normal tissues from 241 individual patients were used to screen for SIBLING and MMP expression in nine distinct cancer types. Results: Significantly elevated expression levels were observed for BSP in cancer of the breast, colon, stomach, rectum, thyroid, and kidney; OPN in cancer of the breast, uterus, colon, ovary, lung, rectum, and thyroid; DMP1 in cancer of the breast, uterus, colon, and lung; and dentin sialophosphoprotein in breast and lung cancer. The degree of correlation between a SIBLING and its partner MMP was found to be significant within a given cancer type (e.g., BSP and MMP-2 in colon cancer, OPN and MMP-3 in ovarian cancer; DMP1 and MMP-9 in lung cancer). The expression levels of SIBLINGS were distinct within subtypes of cancer (e.g., breast dactal tumors compared with lobular tumors). In general, SIBLING expression increased with cancer stage for breast, colon, lung, and rectal cancer. Conclusions: These results suggest SIBLINGS as potential markers of early disease progression in a number of different cancer types, some of which currently lack vigorous clinical markers.

Original languageEnglish (US)
Pages (from-to)8501-8511
Number of pages11
JournalClinical Cancer Research
Volume10
Issue number24
DOIs
StatePublished - Dec 15 2004

Fingerprint

Integrins
Glycoproteins
Breast Neoplasms
Ligands
Gene Expression
Integrin-Binding Sialoprotein
Matrix Metalloproteinases
Osteopontin
Dentin
Neoplasms
Colonic Neoplasms
Lung Neoplasms
Uterine Neoplasms
Rectum
Thyroid Gland
Colon
Matrix Metalloproteinase 3
Bone Neoplasms
Lung
Bone Matrix

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. / Fislier, Larry W.; Jain, Alka; Tayback, Matt; Fedarko, Neal S.

In: Clinical Cancer Research, Vol. 10, No. 24, 15.12.2004, p. 8501-8511.

Research output: Contribution to journalArticle

Fislier, Larry W. ; Jain, Alka ; Tayback, Matt ; Fedarko, Neal S. / Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 24. pp. 8501-8511.
@article{3fa2713cf5ba420194dd32db34de3fe8,
title = "Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers",
abstract = "Purpose: Members of the small integrin binding ligand N-linked glycoprotein (SIBLING) gene family have the capacity to bind and modulate the activity of matrix metalloproteinases (MMPs). The expression levels of five SIBLING gene family members [bone sialoprotein (BSP), osteopontin (OPN), dentin matrix protein 1 (DMP1), matrix extracellular phosphoglycoprotein (MEPE), and dentin sialophosphoprotein (DSPP)] and certain MMPs were determined using a commercial cancer array. Experimental Design: Cancer profiling arrays containing normalized cDNA from both tumor and corresponding normal tissues from 241 individual patients were used to screen for SIBLING and MMP expression in nine distinct cancer types. Results: Significantly elevated expression levels were observed for BSP in cancer of the breast, colon, stomach, rectum, thyroid, and kidney; OPN in cancer of the breast, uterus, colon, ovary, lung, rectum, and thyroid; DMP1 in cancer of the breast, uterus, colon, and lung; and dentin sialophosphoprotein in breast and lung cancer. The degree of correlation between a SIBLING and its partner MMP was found to be significant within a given cancer type (e.g., BSP and MMP-2 in colon cancer, OPN and MMP-3 in ovarian cancer; DMP1 and MMP-9 in lung cancer). The expression levels of SIBLINGS were distinct within subtypes of cancer (e.g., breast dactal tumors compared with lobular tumors). In general, SIBLING expression increased with cancer stage for breast, colon, lung, and rectal cancer. Conclusions: These results suggest SIBLINGS as potential markers of early disease progression in a number of different cancer types, some of which currently lack vigorous clinical markers.",
author = "Fislier, {Larry W.} and Alka Jain and Matt Tayback and Fedarko, {Neal S}",
year = "2004",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1072",
language = "English (US)",
volume = "10",
pages = "8501--8511",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers

AU - Fislier, Larry W.

AU - Jain, Alka

AU - Tayback, Matt

AU - Fedarko, Neal S

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Purpose: Members of the small integrin binding ligand N-linked glycoprotein (SIBLING) gene family have the capacity to bind and modulate the activity of matrix metalloproteinases (MMPs). The expression levels of five SIBLING gene family members [bone sialoprotein (BSP), osteopontin (OPN), dentin matrix protein 1 (DMP1), matrix extracellular phosphoglycoprotein (MEPE), and dentin sialophosphoprotein (DSPP)] and certain MMPs were determined using a commercial cancer array. Experimental Design: Cancer profiling arrays containing normalized cDNA from both tumor and corresponding normal tissues from 241 individual patients were used to screen for SIBLING and MMP expression in nine distinct cancer types. Results: Significantly elevated expression levels were observed for BSP in cancer of the breast, colon, stomach, rectum, thyroid, and kidney; OPN in cancer of the breast, uterus, colon, ovary, lung, rectum, and thyroid; DMP1 in cancer of the breast, uterus, colon, and lung; and dentin sialophosphoprotein in breast and lung cancer. The degree of correlation between a SIBLING and its partner MMP was found to be significant within a given cancer type (e.g., BSP and MMP-2 in colon cancer, OPN and MMP-3 in ovarian cancer; DMP1 and MMP-9 in lung cancer). The expression levels of SIBLINGS were distinct within subtypes of cancer (e.g., breast dactal tumors compared with lobular tumors). In general, SIBLING expression increased with cancer stage for breast, colon, lung, and rectal cancer. Conclusions: These results suggest SIBLINGS as potential markers of early disease progression in a number of different cancer types, some of which currently lack vigorous clinical markers.

AB - Purpose: Members of the small integrin binding ligand N-linked glycoprotein (SIBLING) gene family have the capacity to bind and modulate the activity of matrix metalloproteinases (MMPs). The expression levels of five SIBLING gene family members [bone sialoprotein (BSP), osteopontin (OPN), dentin matrix protein 1 (DMP1), matrix extracellular phosphoglycoprotein (MEPE), and dentin sialophosphoprotein (DSPP)] and certain MMPs were determined using a commercial cancer array. Experimental Design: Cancer profiling arrays containing normalized cDNA from both tumor and corresponding normal tissues from 241 individual patients were used to screen for SIBLING and MMP expression in nine distinct cancer types. Results: Significantly elevated expression levels were observed for BSP in cancer of the breast, colon, stomach, rectum, thyroid, and kidney; OPN in cancer of the breast, uterus, colon, ovary, lung, rectum, and thyroid; DMP1 in cancer of the breast, uterus, colon, and lung; and dentin sialophosphoprotein in breast and lung cancer. The degree of correlation between a SIBLING and its partner MMP was found to be significant within a given cancer type (e.g., BSP and MMP-2 in colon cancer, OPN and MMP-3 in ovarian cancer; DMP1 and MMP-9 in lung cancer). The expression levels of SIBLINGS were distinct within subtypes of cancer (e.g., breast dactal tumors compared with lobular tumors). In general, SIBLING expression increased with cancer stage for breast, colon, lung, and rectal cancer. Conclusions: These results suggest SIBLINGS as potential markers of early disease progression in a number of different cancer types, some of which currently lack vigorous clinical markers.

UR - http://www.scopus.com/inward/record.url?scp=11144227593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144227593&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1072

DO - 10.1158/1078-0432.CCR-04-1072

M3 - Article

C2 - 15623631

AN - SCOPUS:11144227593

VL - 10

SP - 8501

EP - 8511

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -